Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711035 · ClinicalTrials.gov registry record · Phase 1
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00711035 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 50 participants.
The verdict
NCT00711035, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This trial is designed to evaluate the feasibility, safety and efficacy of most closely HLA-matched multivirus specific CTL lines (CHM-CTLs) in HSCT patients with EBV, CMV or adenovirus infections that are persistent despite standard therapy. The primary objective of the study is to assess safety and feasibility of administering CTLs. Survival data will be collected by asking the transplant center to submit the routine Transplant Essential Data form that is sent to the Stem Cell Transplant Outcomes Database at 100 days and 1 year and includes data on survival status and other outcome measures.
Interventions
- BIOLOGICAL Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711035
The ClinicalTrials.gov registry entry for NCT00711035 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection is the first listed.
NCT00711035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711035 about?
NCT00711035 is a clinical study titled "Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)". This trial is designed to evaluate the feasibility, safety and efficacy of most closely HLA-matched multivirus specific CTL lines (CHM-CTLs) in HSCT patients with EBV, CMV or adenovirus infections that are persistent despite standard therapy. The primary objective of the study is to assess safety a...
What is the current status of trial NCT00711035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2008-11. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00711035?
The interventions under investigation include: Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00711035?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.